Antibody raised against PDE2A, a cyclic nucleotide phosphodiesterase specific for second messengers cAMP and cGMP.
Catalogue number crb2005662 Antibody Anti-PDE2A antibody Antigen Peptide KLH conjugated synthetic peptide crb1200871e Protein ID O00408 PDE2A Aliases cGMP-dependent 3',5'-cyclic phosphodiesterase, Cyclic GMP-stimulated phosphodiesterase, CGS-PDE, cGSPDE Cross-Reactivity Mouse, Rat, Cattle Target Protein Species Mouse, Rat, Cattle Host Species Rabbit Antibody Type Polyclonal Concentration 2.5mg/ml Glycine (R1G), 2.0mg/ml Glycine (R2G) Target PDE2A Storage Stabilisers The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Family Cyclic nucleotide phosphodiesterase family. PDE2 subfamily. Storage The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. References
Farmer, R., et al. (2020). Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease. Cellular Signalling, 70, p.109592.
Russwurm, C., et al. (2009). Dual Acylation of PDE2A Splice Variant 3: TARGETING TO SYNAPTIC MEMBRANES *. Journal of Biological Chemistry, 284(38), pp.25782–25790.
Trabanco, A.A., Buijnsters, P. and Rombouts, F.J.R. (2016). Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 – present). Expert Opinion on Therapeutic Patents, 26(8), pp.933–946.
PDEs are a family of phosphohydrolyases, used to catalyse hydrolysis of 3’ cyclic phosphate bonds in the second messengers adenosine and guanine 3’, 5’ cyclic monophosphates (cAMP and cGMP). Physiologically, PDE2A is a locus for communication between cAMP and cGMP signalling pathways, regulating this process through degradation of cAMP and cGMP. This is particularly noteworthy in cells where cAMP and cGMP regulate opposing cell functions.
PDE2A is expressed both in the periphery and central nervous system, but is found in highest concentration in the brain; implying that PDE2A is necessary in regulation of interneuronal cAMP and cGMP involved in emotion, sensory perception and memory. Alteration in cyclic nucleotide signalling is shown cause depression, bipolar disorder and schizophrenia; hence PDE2A, a molecule used to break down cyclic nucleotides, has the potential to be a novel biomarker or therapeutic target for such psychiatric conditions.